MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines.
Overexpression of DNA methyltransferase 1 (DNMT-1) is observed mostly in pancreatic cancer and it can cause tumor suppressor genes silencing in this disease. Recent studies suggest that abnormal expressions of microRNAs (miRs) are involved in pathogenesis of different types of human cancers including pancreatic cancer. In this study we aimed to investigate the effect of miR-148b and -152 on reverting the tumorigenic phenotype of pancreatic cancer cell lines. In order to investigate whether miR-148b and -152 are involved in the regulation of DNMT-1, luciferase reporter assay was used and confirmed that the DNMT-1 mRNA could be a target for miR-148b and miR-152. Furthermore, overexpression of miR-148b and -152 in pancreatic cancer cell lines (MIA PaCa-2 and AsPC-1) decreased DNMT-1 expression (53% and 59% respectively), returned DNA methylation to normal patterns and induced re-expression of tumor suppressor genes, like BNIP3 (4.7- and 3.8-fold) and SPARC (5.3- and 2.9-fold) for miR-148b and -152 respectively. Moreover, the introduced miR-148b and -152 could inhibit the proliferation of MIA PaCa-2 (35% and 37% respectively) and AsPC-1 (39% and 40% respectively) cell lines. The apoptosis rates of MIA PaCa-1 after treatment with miR-148b and -152 were 10% and 8% respectively; while these rates in AsPC-1 were 16% and 11% respectively. Conclusively these findings mean that miRs that are targeting DNMT-1 and modifying methylation status of tumor suppressor genes such as BNIP3 and SPARC can be applied in killing the pancreatic cancer cells and decreasing the tumorigenicity of these cells.
Department of Molecular Medicine; Biotechnology Research Center; Pasteur Institute of Iran; Tehran, Iran.
Masoumeh
M
Azizi
Department of Molecular Medicine; Biotechnology Research Center; Pasteur Institute of Iran; Tehran, Iran.
Ladan
L
Teimoori-Toolabi
Center for Hematology and Regenerative Medicine; Karolinska Institute Huddinge; Stockholm, Sweden.
Mohsen Karimi
MK
Arzanani
Virology Department; Pasteur Institute of Iran; Tehran, Iran.
Kayhan
K
Azadmanesh
Department of Biochemistry; Pasteur Institute of Iran; Tehran, Iran.
Pezhman
P
Fard-Esfahani
Department of Molecular Medicine; Biotechnology Research Center; Pasteur Institute of Iran; Tehran, Iran.
Sirous
S
Zeinali
D017209:Apoptosis; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D000076123:DNA (Cytosine-5-)-Methyltransferase 1; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000235:genetics*; D019175:DNA Methylation; D016147:Genes, Tumor Suppressor / Q000502:physiology*; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*; D015676:Osteonectin / Q000235:genetics / Q000378:metabolism; D010190:Pancreatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000378:metabolism
C090121:BNIP3 protein, human; C550570:MIRN148 microRNA, human; C550856:MIRN152 microRNA, human; D008565:Membrane Proteins; D035683:MicroRNAs; D015676:Osteonectin; D011518:Proto-Oncogene Proteins; C577241:SPARC protein, human; D000076123:DNA (Cytosine-5-)-Methyltransferase 1; D004248:DNA (Cytosine-5-)-Methyltransferases; C000619380:DNMT1 protein, human
DNMT1; methylation; microRNAs; pancreatic neoplasms; tumor suppressor